Table 2.
Univariate analysis for overall survival, progression-free survival, relapse and non-relapse mortality in patients transplanted for relapsed MM.
| OS | PFS | Relapse | NRM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 2 year | 5 year | p | N | 2 year | 5 year | p | 2 year | 5 year | p | 2 year | 5 year | p | |
| Total | ||||||||||||||
| All patients | 159 | 38% (30–46%) | 25% (17–32%) | 140 | 17% (10–23%) | 6% (1–11%) | 68% (60–76%) | 79% (71–86%) | 15% (9–21%) | 15% (9–21%) | ||||
| Patient gender | ||||||||||||||
| Male | 99 | 34% (25–44%) | 20% (11–29%) | 0.149 | 86 | 19% (10–28%) | 0.679 | 67% (56–77%) | 0.986 | 14% (7–22%) | 0.679 | |||
| Female | 60 | 44% (31–57%) | 32% (19–44%) | 54 | 13% (4–23%) | 70% (57–82%) | 17% (7–27%) | |||||||
| Donor type | ||||||||||||||
| HLA-HLA | 86 | 48% (38–59%) | 35% (24–46%) | <0.001 | 80 | 24% (15–34%) | <0.001 | 64% (54–75%) | 0.148 | 11% (4–18%) | 0.091 | |||
| Other | 70 | 25% (14–36%) | 9% (0–17%) | 58 | 3% (0–7%) | 75% (63–87%) | 22% (11–34%) | |||||||
| Interval between allos | HR = 0.94 (0.89–1) | 0.0654 | HR = 0.92 (0.86–0.98) | 0.0078 | HR = 0.89 (0.83–0.96) | 0.0021 | HR = 1.03 (0.9–1.17) | 0.7126 | ||||||
| <2 years | 47 | 26% (13–39%) | 10% (1–20%) | 0.005 | 43 | 9% (0–18%) | 0.02 | 77% (63–90%) | 0.083 | 15% (4–25%) | 0.896 | |||
| ≥2 years | 112 | 43% (34–53%) | 31% (21–40%) | 97 | 20% (12–28%) | 65% (55–74%) | 16% (8–23%) | |||||||
| Disease stage | ||||||||||||||
| Low | 60 | 42% (29–55%) | 24% (11–37%) | 0.747 | 53 | 18% (7–29%) | 0.265 | 57% (44–71%) | 0.009 | 25% (13–37%) | 0.03 | |||
| Advanced | 85 | 33% (23–44%) | 20% (10–29%) | 78 | 12% (5–20%) | 77% (68–87%) | 11% (4–18%) | |||||||
| Second HSCT year | HR = 1.02 (0.99–1.05) | 0.2591 | HR = 1.01 (0.98–1.03) | 0.6997 | HR = 1 (0.97–1.03) | 0.8816 | HR = 1.02 (0.95–1.09) | 0.5503 | ||||||
| 1994–2008 | 81 | 35% (24–45%) | 25% (15–34%) | 0.377 | 71 | 18% (9–27%) | 0.711 | 68% (57–78%) | 0.489 | 14% (6–22%) | 0.652 | |||
| >2008 | 78 | 42% (30–53%) | 22% (9–34%) | 69 | 14% (5–23%) | 69% (58–81%) | 17% (8–26%) | |||||||
| Age at 2nd Tx | HR = 1.09 (0.88–1.35) | 0.4374 | HR = 1.04 (0.84–1.28) | 0.724 | HR = 1.19 (0.93–1.50) | 0.1618 | HR = 0.58 (0.36–0.95) | 0.03 | ||||||
| <50 | 65 | 38% (26–51%) | 29% (18–41%) | 0.601 | 60 | 20% (10–30%) | 0.665 | 56% (43–69%) | 0.021 | 24% (13–35%) | 0.018 | |||
| 50–70 | 94 | 38% (28–48%) | 20% (10–30%) | 80 | 14% (6–22%) | 77% (67–87%) | 9% (3–15%) | |||||||
| Karnofsky score | ||||||||||||||
| <90 | 33 | 30% (13–46%) | 25% (8–41%) | 0.212 | 28 | 12% (0–25%) | 0.523 | 76% (60–93%) | 0.142 | 11% (0–23%) | 0.252 | |||
| 90–100 | 50 | 43% (29–57%) | 20% (6–34%) | 44 | 16% (5–28%) | 60% (45–75%) | 24% (11–36%) | |||||||
| Stem cell source | ||||||||||||||
| BM | 15 | 46% (20–71%) | 27% (2–52%) | 0.966 | 14 | 7% (0–21%) | 0.108 | 79% (57–100%) | 0.196 | 14% (0–33%) | 0.95 | |||
| PB | 141 | 38% (30–46%) | 25% (17–33%) | 125 | 18% (11–25%) | 66% (58–75%) | 16% (9–22%) | |||||||
| Conditioning intensity | ||||||||||||||
| Standard | 60 | 37% (24–49%) | 27% (15–40%) | 0.702 | 52 | 15% (5–25%) | 0.868 | 67% (54–80%) | 0.98 | 18% (7–28%) | 0.822 | |||
| Reduced | 73 | 43% (31–55%) | 23% (12–34%) | 66 | 19% (9–29%) | 65% (53–77%) | 16% (7–24%) | |||||||
| MM | ||||||||||||||
| IgG | 77 | 44% (32–55%) | 29% (18–40%) | 0.282 | 69 | 24% (13–34%) | 0.285 | 60% (48–72%) | 0.385 | 16% (8–25%) | 0.524 | |||
| IgA | 33 | 36% (20–53%) | 15% (1–29%) | 29 | 7% (0–16%) | 72% (56–89%) | 21% (6–35%) | |||||||
| Light chain | 36 | 32% (15–49%) | 27% (11–44%) | 32 | 12% (0–25%) | 78% (63–93%) | 10% (0–20%) | |||||||
| EBMT risk score | ||||||||||||||
| <5 | 21 | 57% (35–78%) | 42% (18–66%) | 0.086 | 20 | 34% (13–55%) | 0.281 | 36% (15–58%) | 0.057 | 30% (10–50%) | 0.115 | |||
| 5 | 72 | 38% (27–50%) | 18% (8–28%) | 69 | 9% (2–16%) | 75% (64–85%) | 17% (8–25%) | |||||||
| >5 | 51 | 27% (14–40%) | 19% (7–31%) | 41 | 15% (3–26%) | 75% (62–89%) | 10% (1–20%) | |||||||
Bold values indicate statistical significance P < 0.05.